On November 11, Nuochengjianhua announced that the phase I clinical trial of ICP-B381, a new drug targeting PSMA and STEAP1 dual-antibody ADC developed by the company, has completed the first patient enrollment to treat solid tumors such as prostate cancer.

Zhitongcaijing · 5d ago
On November 11, Nuochengjianhua announced that the phase I clinical trial of ICP-B381, a new drug targeting PSMA and STEAP1 dual-antibody ADC developed by the company, has completed the first patient enrollment to treat solid tumors such as prostate cancer.